The Convergence of Science and Hope

Argos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. The Company has developed a pipeline of products based on its proprietary Arcelis technology platform.

View the Arcelis Platform

hp_adapt_its_personal

Argos in The News

7966727963517945725adaf646-c8e9-4688-8400-324bb93b1c5058393312-8ab6-4db5-8faa-d7886a5da19f4b3cce63-1ec7-46eb-9496-a1a94a8ec60bARGS_News_2014_11_25_General_Releases.pdfARGS_News_2014_11_24_General_Releases.pdfARGS_News_2014_11_13_General_Releases.pdf1807724615334541232014-11-25T9:35:0-5:02014-11-24T8:30:0-5:02014-11-13T16:5:0-5:0884863884537882950General ReleasesGeneral ReleasesGeneral ReleasesRed Herring Editorial Team Highlights the Argos Arcelis(R) Technology Platform for Developing Fully Personalized Immunotherapies as Important Advance in the Life Science Market.Conference Call and Webcast Today, November 13th, at 4:30 p.m. ETArgos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare ConferenceArgos Therapeutics Receives 2014 Red Herring North America Top 100 AwardArgos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights757575201420142014No Error0

Argos Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Read more

Argos Therapeutics Receives 2014 Red Herring North America Top 100 Award
Read more

Argos Therapeutics Reports Third Quarter 2014 Financial Results and Operational Highlights
Read more

> More News & Events Here.

1999

When Our Company Was Founded

2006

First Arcelis product (AGS-003) clinical trial initiated in mRCC

2013

Phase 3 mRCC ADAPT Study Launched

180

Newly diagnosed RCC patients daily in the US, of which ~ 30 will present with stage IV or metastatic RCC